天士力：10月23日召开董事会会议

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. held its 15th meeting of the 9th Board of Directors on October 23, 2025, to review the Q3 2025 report and other documents [1] Company Summary - For the fiscal year 2024, the revenue composition of Tasly is as follows: Traditional Chinese Medicine accounts for 70.89%, Chemical Preparations 15.38%, Pharmaceutical Commerce 10.53%, Biopharmaceuticals 2.25%, and Chemical Raw Materials 0.61% [1] - As of the report date, Tasly's market capitalization stands at 23.5 billion yuan [1] Industry Summary - In 2023, Chinese innovative drugs have generated overseas licensing sales of 80 billion USD [1] - The secondary market for biomedicine is experiencing a surge, while the primary market is facing challenges in fundraising [1]